Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutikizumab in Erosive Hand Osteoarthritis
NCT02384538Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2015
- Primary completion
- Jul 2016
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
01
Overview
Phase 2, randomised, double-blind trial in erosive hand osteoarthritis (EHOA) comparing Placebo with ABT-981 (2 arms). Primary endpoint: Australian/Canadian Hand Osteoarthritis Index (AUSCAN NR3.1) Pain Subdomain Score at Week 16. Started Mar 2015; status: completed.
02
Drugs
lutikizumab
03
Conditions
erosive hand osteoarthritis (EHOA)
Beyond the preview
Go deeper on NCT02384538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02384538.